CA3159698A1 - Modulators of programmed death-ligand-1 and/or programmed death-ligand-2 - Google Patents

Modulators of programmed death-ligand-1 and/or programmed death-ligand-2 Download PDF

Info

Publication number
CA3159698A1
CA3159698A1 CA3159698A CA3159698A CA3159698A1 CA 3159698 A1 CA3159698 A1 CA 3159698A1 CA 3159698 A CA3159698 A CA 3159698A CA 3159698 A CA3159698 A CA 3159698A CA 3159698 A1 CA3159698 A1 CA 3159698A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
cancer
hydrogen
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3159698A
Other languages
English (en)
French (fr)
Inventor
Mark J. Suto
Bini MATHEW
Rebecca BOOHAKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Research Institute
Original Assignee
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Research Institute filed Critical Southern Research Institute
Publication of CA3159698A1 publication Critical patent/CA3159698A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3159698A 2019-12-04 2020-12-03 Modulators of programmed death-ligand-1 and/or programmed death-ligand-2 Pending CA3159698A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943728P 2019-12-04 2019-12-04
US62/943,728 2019-12-04
PCT/US2020/063137 WO2021113528A1 (en) 2019-12-04 2020-12-03 Modulators of programmed death-ligand-1 and/or programmed death-ligand-2

Publications (1)

Publication Number Publication Date
CA3159698A1 true CA3159698A1 (en) 2021-06-10

Family

ID=76222302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3159698A Pending CA3159698A1 (en) 2019-12-04 2020-12-03 Modulators of programmed death-ligand-1 and/or programmed death-ligand-2

Country Status (6)

Country Link
US (1) US12098216B2 (enExample)
EP (1) EP4069270A4 (enExample)
JP (1) JP2023505221A (enExample)
AU (1) AU2020396100A1 (enExample)
CA (1) CA3159698A1 (enExample)
WO (1) WO2021113528A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144373B1 (en) 1999-01-13 2005-10-19 Genentech, Inc. Serine protease inhibitors
GB0514071D0 (en) * 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
EP3092244B1 (en) 2014-01-10 2019-08-14 Cornell University Dipeptides as inhibitors of human immunoproteasomes
WO2019084455A1 (en) 2017-10-26 2019-05-02 Southern Research Institute DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS

Also Published As

Publication number Publication date
JP2023505221A (ja) 2023-02-08
US12098216B2 (en) 2024-09-24
WO2021113528A1 (en) 2021-06-10
EP4069270A1 (en) 2022-10-12
EP4069270A4 (en) 2024-01-03
AU2020396100A1 (en) 2022-06-16
US20230029187A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
AU2025203542A1 (en) Triaryl compounds for treatment of PD-L1 diseases
CN120699028A (zh) Nek7激酶的抑制剂
AU2019256465B2 (en) 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
CA2887435A1 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
CA2890359A1 (en) Substituted gemcitabine aryl amide analogs and treatment methods using same
EP4424377A2 (en) Benzimidazoles and methods of using same
WO2020198526A2 (en) Small molecule modulators of pank
EP4263554A1 (en) Tricyclic pyrimidines as cyclin-dependent kinase 7 (cdk7) inhibitors
EP4274559A1 (en) Modulators of programmed death-ligand-1
CA3159698A1 (en) Modulators of programmed death-ligand-1 and/or programmed death-ligand-2
CN111447931B (zh) 抗癌/抗纤维化化合物
EP4460294A2 (en) Smarca2/4 inhibition as a strategy to treat tumors that harbor aberrant baf assemblies
US12103943B2 (en) Development of novel clofarabine analogs for cancer therapy
US12215108B2 (en) Development of potential antidotes for arsenicals
WO2024192144A1 (en) Pyrazolopyrimidines as antidotes for arsenicals
WO2025199151A1 (en) Small molecule cereblon binders that induce the degradation of proteins (kdm4b, vcl) relevant to cancer
US20220241310A1 (en) Thiarabine- and thiarabine prodrug-based treatments
WO2024215771A1 (en) Substituted phenyl ethynyl pyrimidines as potent inhibitors of alphaviruses
AU2024275661A1 (en) Compounds that re-activate mutant p53

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250224

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250224

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250319

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250721

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260114